

Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Cellecstar's CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing's Sarcoma

Aug 13 2018, 8:00 AM EDT

Cellecstar Reports 2018 Second Quarter Financial Results and Provides Business Update

Aug 10 2018, 8:00 AM EDT

Cellecstar Biosciences Announces Closing of \$16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Jul 31 2018, 4:05 PM EDT

Stock Overview

Symbol	CLRB
Exchange	Nasdaq
Market Cap	10.79m
Last Price	\$3.00
52-Week	\$2.52 - \$20.40

08/17/2018 04:00 PM EDT

Investor Relations

LHA Investor Relations
Miriam Weber Miller
T: 212-838-3777
MMiller@lhai.com

Management Team

James Caruso

President, CEO and Director

Dr. John Friend

Chief Medical Officer

Jarrold Longcor

Chief Business Officer

Brian M. Posner

Chief Financial Officer

Cellecstar Biosciences, Inc.

3301 Agriculture Drive
Madison, WI 53716

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.